Goldman Sachs predicts that Zepbound, a competitor to Eli Lilly’s Wegovy, will contribute to the growth of the weight-loss drug market to $130 billion by 2030.

Zepbound is Eli Lilly’s new weight-loss drug.Brendan McDermid/ReutersThe anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said.New products such as Eli Lilly’s Zepbound…

Read More: https://www.businessinsider.com/eli-lilly-zepbound-ozempic-wegovy-novo-nordisk-weight-loss-drugs-2024-6